CIK 0001023024 · Large accelerated filer
ANI PHARMACEUTICALS INC
Sign in to watch- Ticker
- ANIP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 582301143
- Phone
- 6097591810
- Business address
- 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540
- Former names
- BIOSANTE PHARMACEUTICALS INC, BEN ABRAHAM TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,939,756
- in 9 filings, $1.9M under 10b5-1 plans
Net −$1,939,756. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-08 | HAUGHEY THOMAS Director | Sale 10b5-1 | −2,000 | $80.88 | $162K | 38,878 |
| 2026-06-05 | CAREY STEPHEN P. SVP & CFO | Option exercise 10b5-1 | +3,312 | $49.51 | $164K | 183,705 |
| 2026-06-05 | CAREY STEPHEN P. SVP & CFO | Sale 10b5-1 | −3,312 | $80.00 | $265K | 180,393 |
| 2026-06-05 | CAREY STEPHEN P. SVP & CFO | Option exercise · Stock Option (right to buy) 10b5-1 | −3,312 | $49.51 | $164K | 6,626 |
| 2026-05-21 | Thoma Jeanne Director | Grant or award | +4,357 | 27,762 | ||
| 2026-05-21 | Leonard Matthew J Director | Grant or award | +4,357 | 11,221 | ||
| 2026-05-21 | Pera Antonio R Director | Grant or award | +4,357 | 27,017 | ||
| 2026-05-21 | TANNENBAUM RENEE P Director | Grant or award | +4,357 | 29,514 | ||
| 2026-05-21 | HAUGHEY THOMAS Director | Grant or award 10b5-1 | +4,357 | 40,878 | ||
| 2026-05-13 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 | −500 | $78.16 | $39K | 78,390 |
| 2026-05-13 | Walsh Patrick D Director | Sale | −10,000 | $80.63 | $806K | 38,432 |
| 2026-05-12 | Gutwerg Ori SVP, GENERICS | Sale | −2,772 | $79.50 | $220K | 78,696 |
| 2026-05-12 | Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | Sale | −459 | $79.21 | $36K | 38,271 |
| 2026-05-11 | Lalwani Nikhil PRESIDENT & CEO | Sale | −55,000 | $77.57 | $4.3M | 349,889 |
| 2026-05-11 | Walsh Patrick D Director | Sale | −3,973 | $80.75 | $321K | 48,432 |
| 2026-04-13 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 | −500 | $77.95 | $39K | 78,890 |
| 2026-03-13 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 | −500 | $72.62 | $36K | 79,390 |
| 2026-03-13 | Mutz Christopher HEAD OF RARE DISEASE | Sale 10b5-1 | −3,162 | $71.64 | $227K | 91,309 |
| 2026-03-11 | Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | Sale | −4,772 | $74.91 | $357K | 38,730 |
| 2026-03-09 | Davis Krista SVP, CHIEF HR OFFICER | Sale 10b5-1 | −5,087 | $74.13 | $377K | 51,946 |
Page 2 of 15 · 282 trades